Answers are grounded in this paper and cite their sources.
Graft-versus-host disease (GVHD) continues to be a common complication of hematopoietic stem cell transplants (SCTs), affecting up to 40% to 60% of patients.1 While acute GVHD has largely been associated with aberrant donor T-cell response, chronic GVHD (cGVHD) is thought to be a more complex reaction involving multiple immune cell lineages. Cutaneous GVHD is known to sometimes flare following modulations in treatment or recent infection.2-4 However, to our knowledge, no cases of cGVHD reactivation secondary to coronavirus disease 2019 (COVID-19) have yet been reported in the literature.
No takes yet. Share an insight, caveat, or question.
Florenzo et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: